Screener
Amylyx Pharmaceuticals, Inc. AMLX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s total liabilities?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported total liabilities of $25.4M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s total liabilities changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s total liabilities decreased by 5.0% year-over-year, from $26.72M to $25.4M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total liabilities?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s total liabilities has grown at a 12.0% compound annual growth rate (CAGR), from $17.43M to $27.39M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude